OPL-CCL2-LPM

OPL-CCL2-LPM is a recombinant fusion protein designed as a leukocyte population modulator for the targeted depletion of CCR2-expressing monocytes and macrophages. It consists of human CCL2 (monocyte chemoattractant protein-1) fused to a truncated, enzymatically active A1 domain of Shigella dysenteriae holotoxin (SA1). The CCL2 portion binds specifically to CCR2 on target leukocytes, facilitating internalization of the fusion protein. Once inside the cell, the SA1 moiety inhibits protein synthesis, leading to selective cell death. This mechanism aims to reduce inflammation and tissue damage in diseases characterized by pathogenic monocyte/macrophage infiltration such as IgA nephropathy. Preclinical studies have shown protective effects in models of nephritis with reductions in macrophage infiltration and glomerular injury. Clinical development has focused on intravenous administration for inflammatory kidney diseases[2][3][5].

Other names

CCL2-LPMCCL-2-LPMCCL 2-LPMleukocyte population modulator